Lifecore Biomedical announced two new contract‑development and manufacturing organization agreements with a U.S. biopharmaceutical customer. The first agreement is a commercial site transfer that will move production of a marketed ophthalmic product from a third‑party CDMO to Lifecore’s U.S. facility. The second agreement expands service offerings for the same product by adding a second delivery system that is currently produced in Europe.
The agreements are expected to generate commercial revenue beginning in 2028. The site transfer will provide the customer with a significant portion of its U.S. production capacity, while the delivery‑system expansion positions Lifecore to capture additional volume and diversify its product mix beyond its core hyaluronic acid portfolio.
Lifecore’s Q4 2025 results showed revenue of $35.7 million, up 10% year‑over‑year, and a transition‑period revenue of $75.5 million, up 20% YoY. Gross margin improved to 31% from 26% in the comparable period, driven by a higher mix of CDMO work and increased manufacturing absorption. Despite these gains, the company reported a net loss of $5.11 million in Q4 and $18.0 million in the transition period, reflecting ongoing investment in capacity and technology.
CEO Paul Josephs highlighted the strategic importance of the new agreements, noting that the site transfer is the fourth commercial transfer signed in five months and that the expansion win underscores Lifecore’s status as a partner‑of‑choice for commercial customers. He added that the company’s technical expertise in qualifying and scaling complex injectable products is a key differentiator that will support future high‑value contracts.
Analysts have noted the company’s improving margin profile and its growing position in the U.S. on‑shoring CDMO market, reflecting confidence in Lifecore’s ability to secure and execute high‑value manufacturing contracts.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.